The release of major special achievements of the national "major new medicine creation" and the National Category 1 new type of new drugs for Gerators will be successfully held.

Qilu.com · Lightning News, June 25th, June 24th to 26th, 2022, by Anhui Medical Association, Fujian Provincial Medical Association, Jiangsu Provincial Medical Association, Shandong Medical Association, Shanghai Medical Association, Zhejiang Medical Association Organized, the "16th East China Gastroenterology Academic Conference and 2022 Shandong Gastroenterology Disease Academic Conference" hosted by the Shandong Medical Association Gastroenterology Branch and hosted by the Provincial Hospital of Shandong Province First Medical University Affiliated Provincial University Hospital was held in Jinan. Well -known domestic and foreign experts at home and abroad Scholars gathered together to explore the latest achievements of the clinical and basic research of digestive diseases. During the conference, the national "major new drug creation" science and technology achievements were released and the national first -class new drugs were listed. The first national chemical innovation medicine for the first national chemical innovation drug in Shandong Province officially appeared in the conference.

This conference specially invited the chairman of the Shandong Medical Association Gastroenterology Branch and Professor Xu Hongwei of Shandong Provincial Hospital as the chairman of the meeting. Yu Hongwen, a member of the Party Group and Deputy Director of the Shandong Provincial Department of Science and Technology, Qin Chengyong, a member of the Party Group, Deputy Director of the Shandong Provincial Health and Health Commission, Qin Chengyong, a first -level inspector, Qiu Bingyu, a first -level inspector of the Shandong Medical Insurance Bureau, a member of the Party Group and Deputy Director of the Shandong Provincial Drug Administration Lin Bingyong, Wang Weijia, executive vice president of the Shandong Medical Industry Association, Professor Li Yanqing, deputy dean of Qilu Hospital of Shandong University, Professor Tian Zibin, Affiliated Hospital of Qingdao University, Song Aigang and Song Liangwei, vice presidents of Luo Xin Pharmaceutical, attended the meeting.

At the beginning of the meeting, Professor Xu Hongwei, chairman of the meeting, delivered a speech. First of all, Professor Xu Hongwei sincerely welcomes the guests, and then he said: "acid -related diseases are common diseases of the digestive department, and acid suppression is the key to the treatment of such diseases. Important. At present, the commonly used acid suppression drugs are PPI, but there are still many unsatisfactory treatment needs. Luo Xin Pharmaceutical actively responded to the country's call for innovation. Gulasheng has made up for the many pain points of the current acid suppression drugs in the treatment process. I look forward to going on on the road of innovation, and at the same time, major innovation results have been widely used in clinical use for Gerators to benefit Chinese patients. "

Subsequently, the representative of the national "major new drug creation" technology major projects shared the research and development process of Takrara to the guests. Song Liangwei, Vice President of Luo Xin Pharmaceutical, said: "Over the years, the country has attached great importance to the innovation research and development of the drug field, the implementation of major new drugs-the implementation of major special projects of science and technology, further improve the national drug innovation system, and encourage innovative drugs with major clinical value. Gulason is a high-tech achievement that has been related to scientific research in nearly 10 years. As the first self-developed P-CAB in China, it brings a new choice for patients with anti-fluid esophagealitis. In the future, Luo Xin Pharmaceutical will adhere to clinical value Guide, with the core of truly solving the needs of patients, accelerate the layout of the innovation and research and development pipelines and the construction of scientific research talents, and develop and produce more high -quality medicines for Chinese patients. "

Professor Tian Zibin, Affiliated Hospital of Qingdao University, elaborated the clinical value of the major national special achievements for Gera. Professor Tian Zibin said that Gerators have a unique mechanism of action, which achieved major breakthroughs in the speed of efficiency, and quickly effectively relieve symptoms in 30 minutes. At the same time Live; no need for acid activation, clinical trials have proved that the mucosa healing rate of 8 weeks is as high as 98.9%, which has a new iteration advantage such as effective control of night acid breakthroughs. This breakthrough innovation will have an important impact on the quality of patients' life and a new choice of medication.

Lin Bingyong, a member of the Party Group and Deputy Director of the Shandong Provincial Drug Administration, delivered a speech. He said: "In recent years, the reform of the national drug review and approval system has continued to deepen, which has stimulated the innovative vitality of pharmaceutical companies and scientific research institutions. Development. Our province actively introduces relevant policies, encourages drug innovation and aggregate development, and gives full play to the policy superposition effect. In 2021, there are three types of innovative drugs in our province. , Include Dellasheng. In the future, the Provincial Drug Administration will establish and implement major innovative products and key construction projects in accordance with the principles of "people who have no self and have me and have me." The actual problems of testing, sample production and other links, strive for more new medicines and good medicines to promote the high -quality development of the drug industry and better meet the demand for public medication. "Finally, the leaders and guests on the stage on the stage to witness the country's major national significance Special results were officially launched for Geradon.

At present, Donorlason has been fully listed in major hospitals, Internet hospitals and retail pharmacies. In the future, with the widespread clinical application of Donora, more patients can benefit from the high -tech achievements of the country's "major new drug creation", transmit health and start a new era of acid suppression treatment.

Further reading:

About tin Gera

Donorlason (product name: Ta Shi Zan®) is a type of innovative medicine independently developed and produced by Luo Xin Pharmaceutical. It is also my country's first self-developed potassium ion competitive stasis (P-CAB). The R & D R & D of Donorra was supported by the "major new drug creation" major national science and technology project and the support of major scientific and technological innovation projects in Shandong Province. In April 2022, it was approved by the State Food and Drug Administration for the treatment of anti -fluid esophagitis for the treatment Improving the quality of life of related patients brings new choices for medication. The approval of Tenkradon not only makes up for pain points such as proton pump inhibitors (PPI) in the treatment of half -life and lack of acid suppression, which leads to low mucosa healing rate, and starts from 30 minutes. The medicine is not affected by the meal, which brings a better treatment experience to the patient. In the future, it is expected to replace PPI to become the mainstream drugs for acid suppressing.

About Luo Xin Pharmaceutical

Luo Xin Pharmaceutical Group Co., Ltd. (referred to as "Luo Xin Pharmaceutical", 002793.SZ) is a large -scale pharmaceutical enterprise group that integrates drug research and development, production, trade and medical and health services. There are R & D and production bases in Shanghai, Chengdu and other places, with more than 6,000 employees. Luo Xin Pharmaceuticals focuses on "transmitting health" as the mission, focusing on solving the unsatisfactory clinical needs of digestion, respiratory, anti -tumor and other diseases, and improving the accessibility of drugs and medical and health services.

Luo Xin Pharmaceutical has a wealthy and competitive product portfolio. Core products are in the leading position of digestion and respiratory diseases. Multiple products of the company are included in the "National Key New Product Plan", "National Torch Plan", and "major new drug creation" and other major technologies. The company has continuously entered the top 100 Chinese pharmaceutical industry since 2006. Since 2011, it has been rated as the best industrial enterprise of China Pharmaceutical R & D product line. A number of product scientific research results have won the second prize of national science and technology progress.

Lightning News reporter Li Miao report